MedTrace Logo

A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies

NCT00055263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-07-28

No results posted yet for this study

Summary

The purposes of this study are to:

* Test the safety of DN-101 in patients with advanced malignancies
* Understand how fast the body absorbs, processes, and eliminates DN-101
* Determine the highest dose of DN-101 that is well tolerated by cancer patients
* Learn how fast the body absorbs, processes, and eliminates DN-101 compared to the approved product

Conditions

  • Neoplasms

Interventions

DRUG

DN-101

Sponsors & Collaborators

  • Novacea

    lead INDUSTRY

Principal Investigators

  • W. David Henner, MD, Ph.D. · Novacea

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055263 on ClinicalTrials.gov